JP2004529928A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529928A5
JP2004529928A5 JP2002582932A JP2002582932A JP2004529928A5 JP 2004529928 A5 JP2004529928 A5 JP 2004529928A5 JP 2002582932 A JP2002582932 A JP 2002582932A JP 2002582932 A JP2002582932 A JP 2002582932A JP 2004529928 A5 JP2004529928 A5 JP 2004529928A5
Authority
JP
Japan
Prior art keywords
hydrogen atom
hydroxy
alkyl
agent according
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002582932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2002/003664 external-priority patent/WO2002085359A1/en
Publication of JP2004529928A publication Critical patent/JP2004529928A/ja
Publication of JP2004529928A5 publication Critical patent/JP2004529928A5/ja
Abandoned legal-status Critical Current

Links

JP2002582932A 2001-04-12 2002-04-12 眼炎症疾患用眼局所処置剤 Abandoned JP2004529928A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28316901P 2001-04-12 2001-04-12
PCT/JP2002/003664 WO2002085359A1 (en) 2001-04-12 2002-04-12 Agent for topical ophthalmic treatment of ocular inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2004529928A JP2004529928A (ja) 2004-09-30
JP2004529928A5 true JP2004529928A5 (enExample) 2005-12-22

Family

ID=23084835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582932A Abandoned JP2004529928A (ja) 2001-04-12 2002-04-12 眼炎症疾患用眼局所処置剤

Country Status (12)

Country Link
US (1) US20020187998A1 (enExample)
EP (1) EP1379247A1 (enExample)
JP (1) JP2004529928A (enExample)
KR (1) KR20040007494A (enExample)
CN (1) CN1503671A (enExample)
AR (1) AR033151A1 (enExample)
BR (1) BR0208939A (enExample)
CA (1) CA2445508A1 (enExample)
MX (1) MXPA03009273A (enExample)
NO (1) NO20034560L (enExample)
NZ (1) NZ529255A (enExample)
WO (1) WO2002085359A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530845A (en) 2001-07-06 2006-03-31 Sucampo Ag Composition for topical administration
KR20040066825A (ko) * 2001-11-19 2004-07-27 노파르티스 아게 아스코마이신의 안검염 치료 용도
US20050239813A1 (en) * 2002-08-09 2005-10-27 Sucampo Pharmaceuticals Inc. Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042890A1 (es) * 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) * 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
WO2015188126A1 (en) * 2014-06-06 2015-12-10 The Schepens Eye Research Institute, Inc. Compositions and methods for treating tumors and immune based inflammatory diseases
PL3470059T3 (pl) * 2015-01-26 2020-11-30 Bausch & Lomb Incorporated Kompozycja zawiesiny okulistycznej
KR101710412B1 (ko) 2015-09-15 2017-02-27 인제대학교 산학협력단 Ycg063을 유효성분으로 함유하는 염증성 안구질환 예방 또는 치료용 약학조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
KR100237715B1 (ko) * 1991-04-26 2000-02-01 후지야마 아키라 안과질환에 대한 마크로라이드 화합물의 용도
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen

Similar Documents

Publication Publication Date Title
JP2004529928A5 (enExample)
US12281111B2 (en) Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
US7820670B2 (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
US10800775B2 (en) Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
ES2684055T3 (es) Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para reducir la presión intraocular
JP2005502621A5 (enExample)
UA124802C2 (uk) Поліциклічні антагоністи tlr7/8 і їх застосування в лікуванні імунних розладів
JP2003509349A5 (enExample)
JP2020507602A5 (enExample)
US20220235043A1 (en) Substituted sulfonamide pyrrolopyridines as jak inhibitors
KR20210074315A (ko) P2x3 길항제를 사용한 소양증의 치료
EP2114398B1 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
JP2005536531A5 (enExample)
KR100192745B1 (ko) 안질환 치료용 5-메틸-이속사졸-4-카르복실산아닐리드 및 2-하이드록시에틸리덴-시아노아세트산아닐리드
US20160108012A1 (en) Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension
WO2003035109A1 (en) Remedies for pruritus
WO2014069554A1 (ja) キヌクリジンアミド誘導体及びその医薬用途
JP2016210780A (ja) アゾール系抗真菌薬の眼瞼皮膚への投与
ES2502515T3 (es) Derivados de naftaleno para el tratamiento de la dermatitis y la psoriasis
JP2003201250A (ja) 掻痒治療剤
JP2021516693A (ja) 乾性眼の予防または治療のための組成物
JP3958391B2 (ja) 眼疾患用薬剤
FR2731618A1 (fr) Composition ophtalmique topique comprenant un derive de 2-(4-(azolylbutyl)-piperazinyl-methyl)-benzimidazole, notamment pour le traitement de la conjonctivite allergique
ES2354516T3 (es) Derivados de pirrolid-2-ona 1,5-disustituida para su uso como agonista del receptor de ep4 en el tratamiento de enfermedades oculares tales como glaucoma.
JPH06263634A (ja) カルシウム拮抗薬